Oculus will be enrolling 40 patients across four different US sites. After completing the trial, Oculus expects to submit top-line data to the FDA, to support its pre-market notification clearance ...
Petaluma biotech Oculus Innovative Sciences saw sharply higher sales of its infection-fighting solutions last quarter but still lost $5.2 million as it continued to spend heavily on clinical trials.
BOULDER, CO / ACCESSWIRE / March 27, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous ...
The Mexican Ministry of Health this week approved the distribution and sale of a hybrid disinfectant and antiseptic, Microcyn 60. Hailed as a "truly disruptive disinfectant" by health care researchers ...
PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a commercial medical technology company that designs, produces and markets safe and effective tissue care products ...
Oculus Innovative Sciences has received an expanded label clearance from the FDA to market Microcyn Rx. The prescription product is indicated for use in managing the debridement of wounds such as ...
PETALUMA — Amneal Enterprises, an affiliation of independent pharmaceutical marketing, discovery and development companies, and Petaluma-based Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today ...
BOULDER, CO / ACCESSWIRE / May 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results